FOUR CHINESE VACCINE COMPANIES DISCUSS DELTA VARIANT: EXISTING VACCINES ARE STILL EFFECTIVE, AND TARGETED VACCINES ARE BEING DEVELOPED2021-07-30 17:21:56 SOURCE: CHINA NEWS NETWORK EDITOR: YIN LIANGBEIJING, JULY 30 (XINHUA) -- FOUR CHINESE VACCINE COMPANIES DISCUSS DELTA VARIANT: EXISTING VACCINES ARE STILL EFFECTIVE, AND TARGETED VACCINES ARE BEING DEVELOPEDREPORTER LI CHUN, HUANG YUQINRECENTLY, THE COVID-19 IN NANJING HAS CONTINUED TO SPREAD, AND THE VIRUS HAS SPREAD TO MANY PROVINCES AND CITIES. THE "BEHIND THE SCENES" IS THE DELTA MUTANT THAT IS NOW "APPEARING" IN MANY COUNTRIES AND PLACES AROUND THE WORLD. DUE TO THE FACT THAT MOST OF THE EARLY INFECTED INDIVIDUALS IN NANJING ARE ALREADY VACCINATED, THE EFFECTIVENESS OF EXISTING VACCINES IN COMBATING VIRAL VARIANTS HAS ONCE AGAIN ATTRACTED WIDESPREAD ATTENTION.THE HEADS OF FOUR VACCINE ENTERPRISES IN CHINA RECENTLY TOLD THE MEDIA THAT THE VACCINES BEING USED ARE STILL EFFECTIVE AGAINST COVID-19 MUTANTS, AND VACCINE RESEARCH AND DEVELOPMENT AGAINST THE MUTANTS ARE ALSO IN FULL SWING."OUR LABORATORY USES THE SERUM OF PEOPLE IMMUNIZED WITH THE VACCINE TO CONDUCT NEUTRALIZATION TEST, AND FOUR TYPICAL VARIANTS, INCLUDING DELTA STRAIN, CAN STILL BE CROSS NEUTRALIZED. IN OTHER WORDS, IT CAN BE EFFECTIVELY PROTECTED." YANG XIAOMING, CHAIRMAN OF SINOPHARM GROUP CHINA BIOTECH, SAID THAT THE COMPANY IS CLOSELY OBSERVING THE MUTATION OF COVID-19, AND WILL TIMELY ADJUST ITS R&D AND PRODUCTION SUPPLY STRATEGY.YANG GUANG, THE CHIEF COMMERCIAL OFFICER OF SINOVAC, ALSO SAID THAT THE COVID-19 MUTANT STRAIN WAS A PROBLEM OF CONSTANT CONCERN. AT PRESENT, SINOVAC HAS OBTAINED VIRUS SAMPLES OF BETA, GAMMA, AND DELTA STRAINS, AND HAS SHOWN SIGNIFICANT RESULTS IN NEUTRALIZING THE SERUM OF SUBJECTS VACCINATED WITH SINOVAC VACCINES WITH DIFFERENT MUTANT STRAINS.AT PRESENT, OUR VACCINE HAS BEEN WIDELY USED IN LATIN AMERICA, INCLUDING THE ****** SCALE REAL-WORLD STUDIES PUBLISHED IN CHILE, WHICH HAVE SHOWN THAT OUR VACCINE HAS A SIGNIFICANT PROTECTIVE EFFECT IN AREAS WHERE THE GAMMA STRAIN IS PREVALENT. YANG GUANG SAID THAT IN TERMS OF THE DELTA STRAIN, SIMILAR RESULTS HAVE BEEN SEEN IN THE COMPREHENSIVE ANTIBODY RESEARCH OF SERUM TO THE GAMMA STRAIN.IN THE VIEW OF THE BUSINESS LEADER OF CONCINO BIOLOGY INTERNATIONAL, AS A VARIATION OF COVID-19, DELTA VIRUS IS STILL COVID-19 IN THE FINAL ANALYSIS. FROM CURRENT CLINICAL RESEARCH BOTH DOMESTICALLY AND INTERNATIONALLY, THESE EXISTING VACCINES CAN EFFECTIVELY PROTECT AGAINST THE DELTA STRAIN, ESPECIALLY IN SEVERE CASES WHERE THEIR EFFECTIVENESS IS STILL VERY GOODIN FACT, THE PROTECTIVE EFFECT OF VACCINES IS DIVIDED INTO THREE LEVELS: PRIMARY PREVENTION IS TO PROTECT THE VACCINATED PERSON FROM INFECTION; SECONDARY PREVENTION IS TO PREVENT THE ONSET OF DISEASE, PREVENT ITS PROGRESSION TO SEVERE ILLNESS OR EVEN DEATH; THE THIRD LEVEL OF PREVENTION IS TO PREVENT INFECTED INDIVIDUALS FROM SPREADING THE VIRUS AGAIN.ZHONG NANSHAN, AN ACADEMICIAN OF THE CAE MEMBER, SAID EARLIER THAT ACCORDING TO THE PRELIMINARY ANALYSIS OF MORE THAN 100 PATIENTS IN GUANGDONG, VACCINATION HAS CERTAIN EFFECTS ON THE DEVELOPMENT OF PNEUMONIA AND SEVERE DISEASE AMONG VACCINATORS. MEDICAL EXPERTS' RESEARCH ON RECENTLY CONFIRMED CASES IN NANJING ALSO FOUND THAT THE PROBABILITY OF COVID-19 PATIENTS WHO HAD BEEN VACCINATED TURNING INTO SEVERE CASES WAS LOW, WHICH ALSO REFLECTED THE EFFECTIVE PROTECTION OF VACCINES.ON THE OTHER HAND, THE VARIATION OF COVID-19 SEEMS TO HAVE BECOME "NORMAL". WHAT IS THE 'COMBAT EFFECTIVENESS' OF EXISTING VACCINES AGAINST MUTANT STRAINS? CAN VACCINE DEVELOPMENT RESPOND QUICKLY TO NEW MUTANT STRAINS OF 'ENEMY'? WHEN WILL HUMANS HAVE THE NEW 'WEAPON' TO ELIMINATE MUTANT STRAINS? THESE ARE ALL QUESTIONS THAT ARE WORTH PAYING ATTENTION TO AND URGENTLY NEED TO BE ANSWERED.AS FOR THE PROTECTIVE EFFECT OF THE EXISTING COVID-19 VACCINE IN THE REAL WORLD, JIANG LINGFENG, VICE CHAIRMAN OF ZHIFEI BIOLOGY, SAID THAT THE COMPANY IS CURRENTLY CONDUCTING INTERNATIONAL MULTI CENTER PHASE III CLINICAL TRIALS IN INDONESIA, UZBEKISTAN, ECUADOR AND OTHER COUNTRIES, AND THE SPECIFIC DATA STILL NEEDS TO BE FURTHER DISCLOSED. ACCORDING TO THE PUBLISHED LABORATORY TEST DATA, ZHIFEI COVID-19 VACCINE STILL HAS GREATER PROTECTION FOR DELTA MUTANT STRAIN THAN THE ORIGINAL STRAIN.JIANG LINGFENG ALSO MENTIONED THAT UPGRADED PRODUCTS TARGETING MUTATED VIRUSES ARE ALSO UNDER DEVELOPMENT, AND THE TEST RESULTS HAVE SHOWN A RELATIVELY OPTIMISTIC PROTECTION EFFICIENCY, BUT FURTHER ANALYSIS IS STILL NEEDED IN PRACTICAL SITUATIONS.YANG XIAOMING STATED THAT CURRENTLY, CHINA NATIONAL PHARMACEUTICAL GROUP (SINOPHARM) CHINA BIOLOGICS IS INTENSIVELY DEVELOPING VACCINES AGAINST VIRAL VARIANTS, INCLUDING EVALUATING THE SAFETY AND EFFICACY OF THE VACCINES. AFTER THE VIRUS MUTATES, THERE ARE A SET OF REGULATORY REQUIREMENTS FOR THE DEVELOPMENT OF NEW MUTANT VACCINES, WHICH REQUIRE TIME AND EXPERIMENTS TO VERIFY.YANG GUANG ALSO REVEALED THAT BASED ON EXISTING PLATFORMS, PROCEDURES, AND QUALITY CONTROL STANDARDS, SINOVAC IS USING THE DELTA STRAIN FOR NEW VACCINE PRODUCTION PROCESSES. THE NEXT STEP WILL CONTINUE TO ADVANCE RELEVANT RESEARCH AND WE HOPE TO PROVIDE MORE DATA TO THE PUBLIC.THE FIRST RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR) FOR AEROSOL INHALATION IN THE WORLD, JOINTLY DEVELOPED BY CONCINO AND CHEN WEI FROM THE MILITARY MEDICAL RESEARCH INSTITUTE OF THE PLA ACADEMY OF MILITARY SCIENCES, HAS RECENTLY RELEASED PHASE I CLINICAL TRIAL DATA. THE HEAD OF INTERNATIONAL BUSINESS AT CANSINO BIOLOGICS REVEALED THAT BASED ON CURRENT CLINICAL DATA, THE VACCINE IS SAFE, EFFECTIVE, AND HAS GOOD ECONOMIC BENEFITS, AND EVERYTHING IS PROGRESSING SMOOTHLY. SUBSEQUENT CLINICAL TRIALS, INDUSTRIALIZATION, AND OTHER RELATED WORK ARE ALSO PROGRESSING IN AN ORDERLY MANNER.HE ALSO CALLED FOR VACCINES TO BE SHARED AND FOR COUNTRIES TO WORK TOGETHER TO MAKE THEM TRULY PUBLIC GOODS. THE ULTIMATE GOAL OF OUR IMMUNIZATION VICTORY IS TO ACHIEVE GLOBAL IMMUNITYYANG XIAOMING ALSO POINTED OUT THAT NO VACCINE HAS A 100% PROTECTIVE EFFICACY. COVID-19 IS VERY SAFE AND EFFECTIVE IN CLINICAL TRIALS AND LARGE POPULATION USE. NOT GETTING VACCINATED INCREASES THE RISK. GETTING VACCINATED SIGNIFICANTLY REDUCES THE RISK OF INFECTION AND PROGRESSION TO SEVERE ILLNESS. THEREFORE, IT IS IMPORTANT TO GET VACCINATED AS EARLY AS POSSIBLE